CTBO (Cantabio Pharmaceuticals) Debt-to-Asset : 4.32 (As of Dec. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cantabio Pharmaceuticals Debt-to-Asset?

Cantabio Pharmaceuticals CTBO Debt-to-Asset is 4.32 as of Dec. 2018.

Cantabio Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2018 was $1.41 Mil. Cantabio Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2018 was $0.00 Mil. Cantabio Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2018 was $0.33 Mil. Cantabio Pharmaceuticals's debt to asset for the quarter that ended in Dec. 2018 was 4.32.

Cantabio Pharmaceuticals  (OTCPK:CTBO) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Cantabio Pharmaceuticals Debt-to-Asset Related Terms

Cantabio Pharmaceuticals Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Cantabio Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantabio Pharmaceuticals Debt-to-Asset Chart

Cantabio Pharmaceuticals Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
Debt-to-Asset
Get a 7-Day Free Trial 0.00 0.00 0.00 10.85 11.06

Cantabio Pharmaceuticals Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.70 11.06 9.04 74.59 4.32

CTBO vs TNTY, ETNI, NTRR: Debt-to-Asset Comparison

For the Biotechnology subindustry, Cantabio Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cantabio Pharmaceuticals Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cantabio Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Cantabio Pharmaceuticals's Debt-to-Asset falls into.


Cantabio Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Cantabio Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Mar. 2018 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1.205 + 0) / 0.109
=11.06

Cantabio Pharmaceuticals's Debt-to-Asset for the quarter that ended in Dec. 2018 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1.409 + 0) / 0.326
=4.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 4.32 mean?
Cantabio Pharmaceuticals (CTBO) has a Debt-to-Asset of 4.32 as of Dec. 2018. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Cantabio Pharmaceuticals and its competitors.
Is Cantabio Pharmaceuticals' Debt-to-Asset too high?
Cantabio Pharmaceuticals' current Debt-to-Asset is 4.32.
How does Cantabio Pharmaceuticals' Debt-to-Asset compare to TNTY and ETNI?
Cantabio Pharmaceuticals' Debt-to-Asset of 4.32 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Cantabio Pharmaceuticals and its competitors. Cantabio Pharmaceuticals's current Debt-to-Asset is 4.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantabio Pharmaceuticals stock overvalued right now?
Cantabio Pharmaceuticals (CTBO) has a current Debt-to-Asset of 4.32. The current Debt-to-Asset is 4.32. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Cantabio Pharmaceuticals (CTBO), the current Debt-to-Asset is 4.32 as of Dec. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantabio Pharmaceuticals Business Description

Address 1250 Oakmead Parkway, Sunnyvale, CA, USA, 94085
Cantabio Pharmaceuticals Inc is the United States based preclinical stage biotechnology company. It is focused on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson's disease and Alzheimer's disease and other related diseases. In addition, In addition, it is also engaged in the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins which display loss of function during disease conditions.